Search Result

Results for "

TEAD1 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) IAP (2) Ligands for Target Protein for PROTAC (1) PROTACs (4) SNIPERs (3) YAP (25)
By Research Areas:	Cancer (24) Inflammation/Immunology (1) Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-134956

VT104 3 Publications Verification	YAP	Cancer
VT104 is a potent and orally active YAP/TAZ inhibitor. VT104 prevents palmitoylation of endogenous TEAD1 and TEAD3 proteins. VT104 can be used in research of cancer .

HY-147136

MYF-03-176 1 Publications Verification	YAP	Cancer
MYF-03-176 is an orally active inhibitor of *TEAD, and suppresses TEAD* transcriptional activity with an IC₅₀ of 11 nM. The IC₅₀ values of MYF-03-176 for TEAD1, TEAD3, and TEAD4 are 47, 32, and 71 nM, respectively. MYF-03-176 inhibits hippo signaling defective malignant pleural mesothelioma (MPM) cells. MYF-03-176 shows strong antitumor efficacy in MPM mouse xenograft model .

HY-134955

VT103 5 Publications Verification	YAP	Cancer
VT103, an analog of VT101, is an orally active and selective *TEAD1* protein palmitoylation inhibitor. VT103 inhibits *YAP/TAZ-TEAD* promoted gene transcription, blocks *TEAD* auto-palmitoylation, and disrupts interaction between YAP/TAZ and *TEAD*. VT103 can be used for the research of cancer .

HY-147135

MYF-03-69 1 Publications Verification TEAD-IN-3	YAP Apoptosis	Cancer
MYF-03-69 (TEAD-IN-3) is a covalent and irreversible *TEAD* inhibitor with IC₅₀s of 385, 143, 558 and 173 nM for *TEAD1, TEAD2, TEAD3* and *TEAD4. MYF-03-69 disrupts YAP-TEAD* association, suppresses TEAD transcriptional activity (IC₅₀ = 56 nM) and up-regulates apoptosis gene BMF. MYF-03-69 selectively inhibits mesothelioma cancer cells with defective Hippo signaling. MYF-03-69 can be used for the study of malignant pleural mesothelioma (MPM) .

HY-174275

TEAD1/3/4-IN-1	YAP	Inflammation/Immunology Cancer
TEAD1/3/4-IN-1 is an orally active inhibitor of *TEAD1/3/4. TEAD1/3/4-IN-1 inhibits* the YAP/TAZ-TEAD interaction, with its EC₅₀ being 2 nM. TEAD1/3/4-IN-1 has anti-proliferative activity against NCI-H226 cells. TEAD1/3/4-IN-1 can be used in the research of lung squamous cell carcinoma .

HY-P2244A

YAP-TEAD-IN-1 TFA 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of *YAP-TEAD* interaction (IC₅₀*=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1* (K_d=15 nM) than YAP (50-171) (K_d= 40 nM) .

HY-P2244

YAP-TEAD-IN-1 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 is a potent and competitive inhibitor of?YAP–TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d=40 nM) .

HY-147208

MSC-4106	YAP	Cancer
MSC-4106 is an orally active and potent inhibitor of *YAP/TAZ-TEAD. MSC-4106 inhibits* *TEAD1* or *TEAD3* auto-palmitoylation and shows inhibitory effect on NCI-H226 tumor xenograft model .

HY-161569

TEAD-IN-11	YAP	Cancer
TEAD-IN-11 (compound 38) has a good inhibitory effect on *TEAD1* (IC₅₀=8.7 nM), *TEAD2* (IC₅₀=3.4 nM), *TEAD3* (IC₅₀=5.6 nnM). TEAD-IN-11 has good selective activity against *TEAD1-3* as a covalent inhibitor. TEAD-IN-11 can be used for cancer research .

HY-147088

TEAD-IN-2	YAP	Cancer
TEAD-IN-2 is a novel, orally active inhibitor of transcriptional enhancer associate domain *(TEAD)* and modulates TEAD by ubiquitination and/or degradation by compounds. TEAD-IN-2 can be used for the research of a variety of diseases, disorders or conditions associated with TEAD .

HY-161443

TEAD-IN-9	YAP	Cancer
TEAD-IN-9 (compound 17) is a *TEAD1* inhibitor with an IC₅₀ of 0.29 μM. TEAD-IN-9 targets the palmitoyl pocket of TEAD, thereby effectively inhibiting the binding of YAP-TEAD and blocking the transcriptional function of YAP-TEAD .

HY-168506

MSC-1254	YAP	Cancer
MSC-1254 is a reversible, selective and covalent *TEAD1* inhibitor. MSC-1254 can be used for the study of cancer .

HY-161568

TEAD-IN-10	YAP	Cancer
TEAD-IN-10 (compound 15) has good selective activity and inhibitory effect on *TEAD1* (IC₅₀=14 nM), *TEAD2* (IC₅₀=179 nM) and *TEAD3* (IC₅₀=4 nnM) as a covalent inhibitor. TEAD-IN-10 can be used for cancer research .

HY-170764

M3686	YAP	Cancer
M3686 (Compound 29) is a potent, selective *TEAD1* inhibitor with an IC₅₀ value of 51 nM. M3686 also shows weaker binding activity on *TEAD3. M3686 potently inhibits* cell viability against YAP-dependent NCI-H226 cell line with an IC₅₀ value of 0.06 uM. M3686 shows strong anti-tumor effects in the NCI-H226 xenograft model .

HY-168505

MSC-5046	YAP	Cancer
MSC-5046 is a selective *TEAD1* inhibitor .

HY-169316

YAP/TAZ inhibitor-4	YAP	Cancer
YAP/TAZ inhibitor-4 (Compound 45) is an inhibitor of YAP/TAZ, exhibiting *TEAD* transcriptional activation inhibitory activity by suppressing the binding of YAP or TAZ to *TEAD* .

HY-173139

TEAD-IN-19	YAP	Cancer
TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of *TEAD, exhibiting inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% against TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at a concentration of 10 μM. TEAD-IN-19 shows potent anti-proliferative and anti-migratory activities in prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD*-IN-19 holds promise for research in the field of cancer therapy .

HY-181590

PROTAC TEAD1/IAP degrader-3	PROTACs SNIPERs YAP IAP	Cancer
PROTAC TEAD1/IAP degrader-3 is a *TEAD1/IAP* PROTAC degrader. PROTAC TEAD1/IAP degrader-3 recruits the cIAP1 and XIAP E3 ligases to form a ternary complex, drives proteasomal degradation of *TEAD1, and triggers autoubiquitination and proteasomal degradation of cIAP1. PROTAC TEAD1/IAP* degrader-3 inhibits cell proliferation. PROTAC TEAD1/IAP degrader-3 regulates Hippo pathway activity by downregulating CTGF gene expression in a TEAD-dependent manner. PROTAC TEAD1/IAP degrader-3 is applicable to the research of mesothelioma .

HY-181537

PROTAC TEAD1/IAP degrader-2	PROTACs SNIPERs YAP IAP	Cancer
PROTAC TEAD1/IAP degrader-2 is an IAP-harnessing TEAD1 PROTAC degrader, with a DC₅₀ of 170 nM against TEAD1 in NCI-H2052 cells. PROTAC TEAD1/IAP degrader-2 exhibits moderate antiproliferative activity in Hippo pathway-dependent mesothelioma cells. PROTAC TEAD1/IAP degrader-2 inhibits the expression of CTGF, but with a weaker effect than the TEAD inhibitor VT-107 (HY-134957). PROTAC TEAD1/IAP degrader-2 can be used in mesothelioma-related research .

HY-147209

DC-TEAD3in03	YAP	Metabolic Disease
DC-TEAD3in03 is a subtype-selective and covalent *TEAD3* inhibitor with an IC₅₀ of 0.16 μM. DC-TEAD3in03 exhibits the inhibitory activity on TEAD1/2/4 reduced by more than 100 times. DC-TEAD3in03 has the IC₅₀ for TEAD3 of 1.15 μM in the GAL4-TEAD reporter gene experiment in cells, and it does not interfere with the β-catenin pathway. DC-TEAD3in03 reduces the growth rate of the zebrafish tail fin. DC-TEAD3in03 can be used to study the proportional growth of appendages in vertebrates .

HY-182673

VT102	YAP	Cancer
VT102 is a *TEAD1* inhibitor with a human IC₅₀ of 391 nM. VT102 inhibits auto-palmitoylation, attenuates YAP/TEAD1 interaction, reduces expression of *TEAD* target genes, and inhibits YAP-mediated luciferase reporter activity. VT102 exerts weak cell growth inhibitory activity in cancer cells. VT102 can be used for the research of cancer .

HY-186022

YAP/TAZ-TEAD-IN-3	Ligands for Target Protein for PROTAC YAP	Cancer
YAP/TAZ-TEAD-IN-3 is a *YAP/TAZ-TEAD* interaction inhibitor with an IC₅₀ of 1.8 nM. YAP/TAZ-TEAD-IN-3 can be used as a *TEAD1* ligand to construct PROTACs, such as PROTAC TEAD degrader-2 (HY-186021) .

HY-183753

LC-TD-05	YAP Apoptosis	Cancer
LC-TD-05 is a non-covalent inhibitor of *TEAD1, TEAD2* and *TEAD4, with IC₅₀* values of 116.6 nM, 168.7 nM and 68.3 nM, respectively; it shows weak activity against *TEAD3, with a human IC₅₀* of 1261.0 nM. LC-TD-05 induces apoptosis in hepatocellular carcinoma cells. LC-TD-05 can be used for the research of hepatocellular carcinoma .

HY-186021

PROTAC TEAD degrader-2	PROTACs YAP	Cancer
PROTAC TEAD degrader-2 (Compound 31) is an efficient TEAD1 PROTAC degrader with a DC₅₀ of 0.6 nM. PROTAC TEAD degrader-2 inhibits the *YAP/TAZ-TEAD* interaction, with a IC₅₀ of 1.8 nM. PROTAC TEAD degrader-2 exhibits significant selective inhibitory activity against YAP-dependent cancer cells and effectively suppresses the transcriptional activity mediated by YAP. PROTAC TEAD degrader-2 can be used for research on mesothelioma and glioma .

HY-181594

PROTAC TEAD/IAP degrader-1	PROTACs SNIPERs YAP	Cancer
PROTAC TEAD/IAP degrader-1 is a *TEAD/IAP* PROTAC degrader. PROTAC TEAD/IAP degrader-1 is also a specific and Nongenetic inhibitor of apoptosis protein (IAP)-dependent protein eraser (SNIPERs). PROTAC TEAD/IAP degrader-1 recruits cIAP1 to form ternary complexes, induces ubiquitination, proteasomal *TEAD1, TEAD4* degradation. PROTAC TEAD/IAP degrader-1 inhibits TEAD transcriptional activity, reduces CTGF expression, and reduces cell proliferation. PROTAC TEAD/IAP degrader-1 can be used for the research of mesothelioma .

Cat. No.	상품명	Target	Research Area

HY-P2244A

YAP-TEAD-IN-1 TFA 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of *YAP-TEAD* interaction (IC₅₀*=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1* (K_d=15 nM) than YAP (50-171) (K_d= 40 nM) .

HY-P2244

YAP-TEAD-IN-1 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 is a potent and competitive inhibitor of?YAP–TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d=40 nM) .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

Name
이메일 *

	Sorry, but the email address you supplied was invalid.